Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) Revenue (2020 - 2025)

Historic Revenue for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $18.2 million.

  • Pharming's Revenue fell 7569.37% to $18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $362.3 million, marking a year-over-year increase of 614.1%. This contributed to the annual value of $297.2 million for FY2024, which is 2114.99% up from last year.
  • Per Pharming's latest filing, its Revenue stood at $18.2 million for Q3 2025, which was down 7569.37% from $172.3 million recorded in Q2 2025.
  • Over the past 5 years, Pharming's Revenue peaked at $43.5 billion during Q1 2021, and registered a low of -$43.4 billion during Q2 2021.
  • Its 5-year average for Revenue is $70.3 million, with a median of $74.8 million in 2024.
  • As far as peak fluctuations go, Pharming's Revenue tumbled by 9999.8% in 2022, and later soared by 950034.54% in 2024.
  • Pharming's Revenue (Quarter) stood at $93.2 million in 2021, then tumbled by 41.42% to $54.6 million in 2022, then soared by 48.72% to $81.2 million in 2023, then increased by 14.13% to $92.7 million in 2024, then plummeted by 80.37% to $18.2 million in 2025.
  • Its Revenue was $18.2 million in Q3 2025, compared to $172.3 million in Q2 2025 and $79.1 million in Q1 2025.